Susan G. Komen Breast Cancer Foundation
71
7
16
49
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.5%
6 terminated/withdrawn out of 71 trials
89.1%
+2.6% vs industry average
3%
2 trials in Phase 3/4
31%
15 of 49 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (71)
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Role: collaborator
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
Role: collaborator
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
Role: collaborator
Susan G. Komen's ShareForCures
Role: lead
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Role: collaborator
Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue
Role: collaborator
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
Role: collaborator
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Role: collaborator
Elevate! : An Elderly Breast Cancer Cohort Study
Role: collaborator
Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
Role: collaborator
Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects
Role: collaborator
The Preoperative Health & Body Study
Role: collaborator
NAVAH Impact on Radiation Therapy Completion in Black Breast & Prostate Cancer Patients
Role: collaborator
Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer
Role: collaborator
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
Role: collaborator
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
Role: collaborator
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
Role: collaborator
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
Role: collaborator
Johns Hopkins Breast Cancer Program Longitudinal Repository
Role: collaborator
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Role: collaborator